Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Oncology
1.2 Key Market Segments
1.2.1 Drugs for Oncology Segment by Type
1.2.2 Drugs for Oncology Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Oncology Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Oncology Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Oncology Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Oncology Market Competitive Landscape
3.1 Global Drugs for Oncology Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Oncology Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Oncology Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Oncology Sales Sites, Area Served, Product Type
3.6 Drugs for Oncology Market Competitive Situation and Trends
3.6.1 Drugs for Oncology Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Oncology Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Oncology Industry Chain Analysis
4.1 Drugs for Oncology Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Oncology Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Oncology Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Oncology Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Oncology Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Oncology Price by Type (2019-2024)
7 Drugs for Oncology Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Oncology Market Sales by Application (2019-2024)
7.3 Global Drugs for Oncology Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Oncology Sales Growth Rate by Application (2019-2024)
8 Drugs for Oncology Market Segmentation by Region
8.1 Global Drugs for Oncology Sales by Region
8.1.1 Global Drugs for Oncology Sales by Region
8.1.2 Global Drugs for Oncology Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Oncology Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Oncology Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Oncology Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Oncology Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Oncology Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Roche
9.1.1 Roche Drugs for Oncology Basic Information
9.1.2 Roche Drugs for Oncology Product Overview
9.1.3 Roche Drugs for Oncology Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Drugs for Oncology SWOT Analysis
9.1.6 Roche Recent Developments
9.2 Celgene
9.2.1 Celgene Drugs for Oncology Basic Information
9.2.2 Celgene Drugs for Oncology Product Overview
9.2.3 Celgene Drugs for Oncology Product Market Performance
9.2.4 Celgene Business Overview
9.2.5 Celgene Drugs for Oncology SWOT Analysis
9.2.6 Celgene Recent Developments
9.3 Novartis
9.3.1 Novartis Drugs for Oncology Basic Information
9.3.2 Novartis Drugs for Oncology Product Overview
9.3.3 Novartis Drugs for Oncology Product Market Performance
9.3.4 Novartis Drugs for Oncology SWOT Analysis
9.3.5 Novartis Business Overview
9.3.6 Novartis Recent Developments
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb Drugs for Oncology Basic Information
9.4.2 Bristol-Myers Squibb Drugs for Oncology Product Overview
9.4.3 Bristol-Myers Squibb Drugs for Oncology Product Market Performance
9.4.4 Bristol-Myers Squibb Business Overview
9.4.5 Bristol-Myers Squibb Recent Developments
9.5 Johnson and Johnson
9.5.1 Johnson and Johnson Drugs for Oncology Basic Information
9.5.2 Johnson and Johnson Drugs for Oncology Product Overview
9.5.3 Johnson and Johnson Drugs for Oncology Product Market Performance
9.5.4 Johnson and Johnson Business Overview
9.5.5 Johnson and Johnson Recent Developments
9.6 Merck and Co.
9.6.1 Merck and Co. Drugs for Oncology Basic Information
9.6.2 Merck and Co. Drugs for Oncology Product Overview
9.6.3 Merck and Co. Drugs for Oncology Product Market Performance
9.6.4 Merck and Co. Business Overview
9.6.5 Merck and Co. Recent Developments
9.7 AstraZeneca
9.7.1 AstraZeneca Drugs for Oncology Basic Information
9.7.2 AstraZeneca Drugs for Oncology Product Overview
9.7.3 AstraZeneca Drugs for Oncology Product Market Performance
9.7.4 AstraZeneca Business Overview
9.7.5 AstraZeneca Recent Developments
9.8 Pfizer
9.8.1 Pfizer Drugs for Oncology Basic Information
9.8.2 Pfizer Drugs for Oncology Product Overview
9.8.3 Pfizer Drugs for Oncology Product Market Performance
9.8.4 Pfizer Business Overview
9.8.5 Pfizer Recent Developments
9.9 Amgen
9.9.1 Amgen Drugs for Oncology Basic Information
9.9.2 Amgen Drugs for Oncology Product Overview
9.9.3 Amgen Drugs for Oncology Product Market Performance
9.9.4 Amgen Business Overview
9.9.5 Amgen Recent Developments
9.10 Eli Lilly
9.10.1 Eli Lilly Drugs for Oncology Basic Information
9.10.2 Eli Lilly Drugs for Oncology Product Overview
9.10.3 Eli Lilly Drugs for Oncology Product Market Performance
9.10.4 Eli Lilly Business Overview
9.10.5 Eli Lilly Recent Developments
9.11 AbbVie
9.11.1 AbbVie Drugs for Oncology Basic Information
9.11.2 AbbVie Drugs for Oncology Product Overview
9.11.3 AbbVie Drugs for Oncology Product Market Performance
9.11.4 AbbVie Business Overview
9.11.5 AbbVie Recent Developments
9.12 Takeda
9.12.1 Takeda Drugs for Oncology Basic Information
9.12.2 Takeda Drugs for Oncology Product Overview
9.12.3 Takeda Drugs for Oncology Product Market Performance
9.12.4 Takeda Business Overview
9.12.5 Takeda Recent Developments
9.13 Astellas
9.13.1 Astellas Drugs for Oncology Basic Information
9.13.2 Astellas Drugs for Oncology Product Overview
9.13.3 Astellas Drugs for Oncology Product Market Performance
9.13.4 Astellas Business Overview
9.13.5 Astellas Recent Developments
9.14 Ipsen
9.14.1 Ipsen Drugs for Oncology Basic Information
9.14.2 Ipsen Drugs for Oncology Product Overview
9.14.3 Ipsen Drugs for Oncology Product Market Performance
9.14.4 Ipsen Business Overview
9.14.5 Ipsen Recent Developments
9.15 Sanofi
9.15.1 Sanofi Drugs for Oncology Basic Information
9.15.2 Sanofi Drugs for Oncology Product Overview
9.15.3 Sanofi Drugs for Oncology Product Market Performance
9.15.4 Sanofi Business Overview
9.15.5 Sanofi Recent Developments
9.16 Bayer
9.16.1 Bayer Drugs for Oncology Basic Information
9.16.2 Bayer Drugs for Oncology Product Overview
9.16.3 Bayer Drugs for Oncology Product Market Performance
9.16.4 Bayer Business Overview
9.16.5 Bayer Recent Developments
9.17 Biogen Idec
9.17.1 Biogen Idec Drugs for Oncology Basic Information
9.17.2 Biogen Idec Drugs for Oncology Product Overview
9.17.3 Biogen Idec Drugs for Oncology Product Market Performance
9.17.4 Biogen Idec Business Overview
9.17.5 Biogen Idec Recent Developments
9.18 Teva
9.18.1 Teva Drugs for Oncology Basic Information
9.18.2 Teva Drugs for Oncology Product Overview
9.18.3 Teva Drugs for Oncology Product Market Performance
9.18.4 Teva Business Overview
9.18.5 Teva Recent Developments
9.19 Otsuka
9.19.1 Otsuka Drugs for Oncology Basic Information
9.19.2 Otsuka Drugs for Oncology Product Overview
9.19.3 Otsuka Drugs for Oncology Product Market Performance
9.19.4 Otsuka Business Overview
9.19.5 Otsuka Recent Developments
9.20 Eisai
9.20.1 Eisai Drugs for Oncology Basic Information
9.20.2 Eisai Drugs for Oncology Product Overview
9.20.3 Eisai Drugs for Oncology Product Market Performance
9.20.4 Eisai Business Overview
9.20.5 Eisai Recent Developments
9.21 Merck KGaA
9.21.1 Merck KGaA Drugs for Oncology Basic Information
9.21.2 Merck KGaA Drugs for Oncology Product Overview
9.21.3 Merck KGaA Drugs for Oncology Product Market Performance
9.21.4 Merck KGaA Business Overview
9.21.5 Merck KGaA Recent Developments
9.22 Gilead Sciences
9.22.1 Gilead Sciences Drugs for Oncology Basic Information
9.22.2 Gilead Sciences Drugs for Oncology Product Overview
9.22.3 Gilead Sciences Drugs for Oncology Product Market Performance
9.22.4 Gilead Sciences Business Overview
9.22.5 Gilead Sciences Recent Developments
10 Drugs for Oncology Market Forecast by Region
10.1 Global Drugs for Oncology Market Size Forecast
10.2 Global Drugs for Oncology Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Oncology Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Oncology Market Size Forecast by Region
10.2.4 South America Drugs for Oncology Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Oncology by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Drugs for Oncology Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Oncology by Type (2025-2030)
11.1.2 Global Drugs for Oncology Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Oncology by Type (2025-2030)
11.2 Global Drugs for Oncology Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Oncology Sales (Kilotons) Forecast by Application
11.2.2 Global Drugs for Oncology Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
